Various Key players such as Corcept Therapeutics, Cortendo AB (a subsidiary of Strongbridge Biopharma), and others are in the process of developing potential therapies for the treatment of Endogenous Cushing’s Syndrome.
DelveInsight's "Endogenous Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Endogenous Cushing's Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Endogenous Cushing's Syndrome market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Endogenous Cushing's Syndrome: An Overview
Cushing syndrome is a rare endocrine disorder characterized by various symptoms and physical abnormalities that occur due to excessive amounts of the hormone cortisol, a vital glucocorticoid. Endogenous Cushing syndrome is defined as the syndrome in which the adrenal glands produce too much cortisol. It is one of two types of Cushing syndrome. The other type is exogenous in which glucocorticoids are introduced from outside the body. Endogenous Cushing’s syndrome is a rare, serious, and potentially lethal endocrine disease caused by chronic elevated cortisol exposure - often the result of a benign pituitary gland tumor.
The primary cause of the syndrome directs treatment of Cushing syndrome. In general, therapy aims to reduce cortisol secretion to normal to reduce the risk of comorbidities associated with hypercortisolism. The treatment of choice for endogenous Cushing syndrome is surgical resection of the causative tumor. The primary therapy for Cushing's disease is transsphenoidal surgery, and the primary therapy for adrenal tumors is adrenalectomy. Second-line treatments include medication, bilateral adrenalectomy, and radiation therapy (for corticotrope tumors). Effective treatment includes the normalization of cortisol levels or action. It also includes the normalization of comorbidities (e.g., hypertension, diabetes) by adjunctive treatments (e.g., antihypertensives).
Endogenous Cushing's Syndrome Market Key Facts
-
According to the National Organization of Rare Disorders (NORD) (n.d.), Cushing syndrome, caused by an adrenal or pituitary tumor, affects females five times more frequently than males. Symptoms commonly begin between 25 to 40 years of age. Men are affected 3 times more than women by ectopic ACTH production that is caused by lung cancer, which occurs later in life.
-
According to the study conducted by Etxabe et al. (n.d.), titled “Morbidity and mortality in Cushing's disease: an epidemiological approach,” the average incidence of newly diagnosed cases was 2.4 cases per million people per year. Cushing's disease was more frequent in women than in men, with a ratio of 15:1.
Endogenous Cushing's Syndrome Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Endogenous Cushing's Syndrome market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Endogenous Cushing's Syndrome market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Endogenous Cushing's Syndrome Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Endogenous Cushing's Syndrome Epidemiology, Segmented by -
-
Total Incident Cases of Endogenous Cushing’s Syndrome in the 7MM (2019–2032)
-
Gender-Specific Incident cases of Endogenous Cushing’s Syndrome in the 7MM (2019–2032)
-
Treatable cases of Endogenous Cushing’s Syndrome in the 7MM (2019–2032)
Endogenous Cushing's Syndrome Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Endogenous Cushing's Syndrome market or expected to be launched during the study period. The analysis covers the Endogenous Cushing's Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Endogenous Cushing's Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Endogenous Cushing's Syndrome Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/endogenous-cushings-syndrome-market
Endogenous Cushing's Syndrome Therapeutics Analysis
The Leading Companies in the Endogenous Cushing's Syndrome Therapeutics Market Include:
-
Corcept Therapeutics,
-
Cortendo AB (a subsidiary of Strongbridge Biopharma)
And Many Others
Endogenous Cushing's Syndrome Therapies Covered in the Report Include:
-
Recorlev (Strongbridge Biopharma plc)
-
Relacorilant (Corcept Therapeutics)
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/endogenous-cushings-syndrome-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Endogenous Cushing's Syndrome Competitive Intelligence Analysis
4. Endogenous Cushing's Syndrome Market Overview at a Glance
5. Endogenous Cushing's Syndrome Disease Background and Overview
6. Endogenous Cushing's Syndrome Patient Journey
7. Endogenous Cushing's Syndrome Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Endogenous Cushing's Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Endogenous Cushing's Syndrome Unmet Needs
10. Key Endpoints of Endogenous Cushing's Syndrome Treatment
11. Endogenous Cushing's Syndrome Marketed Products
12. Endogenous Cushing's Syndrome Emerging Drugs and Latest Therapeutic Advances
13. Endogenous Cushing's Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Endogenous Cushing's Syndrome Market Outlook (In US, EU5, and Japan)
16. Endogenous Cushing's Syndrome Access and Reimbursement Overview
17. KOL Views on the Endogenous Cushing's Syndrome Market
18. Endogenous Cushing's Syndrome Market Drivers
19. Endogenous Cushing's Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/endogenous-cushings-syndrome-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
